Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 6/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 4/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025525 | 0.90 | HTR2B (0.47) | HTR2BNAMPTHCRTR1HCRTR2CXCR4 | |
| SCHEMBL14025514 | 0.84 | HTR2B (0.42) | HTR2BNAMPTHCRTR1HCRTR2CXCR4 | |
| SCHEMBL14025489 | 0.84 | KMT2A (0.51) | HTR2BNAMPT | |
| SCHEMBL14025459 | 0.81 | ALDH1A1 (0.45) | FNTAPGGT1BNAMPTFNTBHCRTR1 | |
| SCHEMBL14045814 | 0.81 | FNTA (0.39) | FNTAPGGT1BFNTBCXCR4 | |
| SCHEMBL14025695 | 0.79 | AKR1C3 (0.43) | HTR2BHCRTR1HCRTR2 | |
| SCHEMBL14025484 | 0.78 | MEN1 (0.45) | HTR2BNAMPTCXCR4 | |
| SCHEMBL14025521 | 0.76 | HTR2B (0.42) | HTR2BNAMPTHCRTR1HCRTR2CXCR4 | |
| SCHEMBL14025689 | 0.75 | AKR1C3 (0.37) | HTR2BHCRTR1HCRTR2CXCR4 | |
| SCHEMBL14025696 | 0.74 | KMT2A (0.38) | HTR2BCYP2C9CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | HTR2B 4516/4885CYP2C9 2131/4885FNTA 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.